Journal article · 2026 · Open access

Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity

Thomas J. Schnitzer, D.J. Hunter, P. Conaghan, A.M. Sharma, S.D. Pedersen, K. Chen, S.Y. Park, N. Makarova, K. Giblin, T. Forrester

New England Journal of Medicine · Published 8 November 2026 · DOI 10.1056/nejmoa2610676

Open PDFView at the publisherCite this paper

In brief

“Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity” is a 2026 journal article by Thomas J. Schnitzer and 9 co-authors, published in New England Journal of Medicine. OpenAlex counts 0 citations as of 16 November 2026. It is open access: the full text is free to read at White Rose Research Online (University of Leeds, The University of Sheffield, University of York).

Citations
0
References
24
Authors
10

Abstract

BACKGROUND: Retatrutide, an investigational triple agonist of GIP, GLP-1, and glucagon receptors, may be useful for the treatment of painful knee osteoarthritis in persons with obesity. METHODS: In two phase 3 trials, adults without diabetes who had painful knee osteoarthritis and a body-mass index of at least 27 were randomly assigned to receive once-weekly subcutaneous retatrutide (9 or 12 mg in TRIUMPH-4 and 4, 9, or 12 mg in TRIUMPH-1-OA) or placebo. In TRIUMPH-4, the primary end points were the change in the WOMAC pain score (range, 0 to 10, with higher scores indicating worse pain) and the percent change in body weight at week 68. In TRIUMPH-1-OA, the primary end point was the change in the WOMAC pain score at week 80. For non-pain-related end points, intercurrent events were handled with a treatment-policy strategy. For pain-related end points, a hybrid-treatment estimand was applied, with a hypothetical strategy for intercurrent events that suggested treatment failure and a treatment-policy strategy elsewhere. We also report results for an intention-to-treat (ITT) estimand. RESULTS: A total of 445 participants underwent randomization in TRIUMPH-4 and 574 in TRIUMPH-1-OA. At 68 weeks, the mean changes in the WOMAC pain score (hybrid-treatment estimand) with retatrutide in TRIUMPH-4 were -3.96 (9 mg) and -3.74 (12 mg), versus -2.12 with placebo (difference vs. placebo, -1.83 [95% confidence interval {CI}, -2.37 to -1.30] and -1.61 [95% CI, -2.16 to -1.07], respectively). For the ITT estimand, the corresponding differences from placebo were -1.70 (95% CI, -2.19 to -1.22) and -1.38 (95% CI, -1.91 to -0.85) (P<0.001 for all comparisons). The mean percent changes in body weight with retatrutide were -20.0% (9 mg) and -23.7% (12 mg), versus -4.6% with placebo (difference vs. placebo, -15.4 percentage points [95% CI, -18.7 to -12.1] and -19.2 percentage points [95% CI, -22.4 to -15.9]; P<0.001 for both comparisons). At 80 weeks, the mean changes in the WOMAC pain score (hybrid-treatment estimand) with retatrutide in TRIUMPH-1-OA were -3.22 (4 mg), -3.48 (9 mg), and -3.64 (12 mg), versus -1.87 with placebo (difference vs. placebo, -1.35 [95% CI, -1.92 to -0.78], -1.61 [95% CI, -2.20 to -1.02], and -1.77 [95% CI, -2.34 to -1.20], respectively). For the ITT estimand, the corresponding differences from placebo were -0.96 (95% CI, -1.61 to -0.30), -1.41 (95% CI, -2.07 to -0.75), and -1.64 (95% CI, -2.26 to -1.02) (P≤0.005 for all comparisons). In both trials, serious adverse events were more common with retatrutide than with placebo, and the most common adverse events were gastrointestinal. CONCLUSIONS: In participants with painful knee osteoarthritis…

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Schnitzer, T. J., Hunter, D., Conaghan, P., Sharma, A., Pedersen, S., Chen, K., Park, S., Makarova, N., Giblin, K., & Forrester, T. (2026). Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2610676

MLA 9

Schnitzer, Thomas J., et al. “Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity.” New England Journal of Medicine, 2026. https://doi.org/10.1056/nejmoa2610676.

Chicago

Schnitzer, Thomas J., D.J. Hunter, P. Conaghan, A.M. Sharma, S.D. Pedersen, K. Chen, S.Y. Park, N. Makarova, K. Giblin, and T. Forrester. 2026. “Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity.” New England Journal of Medicine. https://doi.org/10.1056/nejmoa2610676.

Harvard

Schnitzer, T. J. et al. (2026) ‘Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity’, New England Journal of Medicine. doi:10.1056/nejmoa2610676.

IEEE

T. J. Schnitzer et al., “Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity,” New England Journal of Medicine, 2026, doi: 10.1056/nejmoa2610676.

BibTeX

@article{schnitzer2026retatrutide,
  title     = {{Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity}},
  author    = {Schnitzer, Thomas J. and Hunter, D.J. and Conaghan, P. and Sharma, A.M. and Pedersen, S.D. and Chen, K. and Park, S.Y. and Makarova, N. and Giblin, K. and Forrester, T.},
  journal   = {New England Journal of Medicine},
  year      = {2026},
  doi       = {10.1056/nejmoa2610676},
  url       = {https://doi.org/10.1056/nejmoa2610676}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Rheumatology › Osteoarthritis Treatment and Mechanisms

  • retatrutide
  • knee osteoarthritis
  • obesity
  • osteoarthritis pain
  • weight loss
  • WOMAC pain score
  • intercurrent events
  • estimands

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Schnitzer, T. J., Hunter, D., Conaghan, P., Sharma, A., Pedersen, S., Chen, K., Park, S., Makarova, N., Giblin, K., & Forrester, T. (2026). Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2610676

How many times has this paper been cited?

0 times, according to OpenAlex on 16 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at White Rose Research Online (University of Leeds, The University of Sheffield, University of York): sign in and open the PDF from this page.

Who wrote this paper?

Thomas J. Schnitzer, D.J. Hunter, P. Conaghan, A.M. Sharma, S.D. Pedersen, K. Chen, S.Y. Park, N. Makarova, K. Giblin, T. Forrester.

What is the DOI of this paper?

10.1056/nejmoa2610676, permanently at https://doi.org/10.1056/nejmoa2610676. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 16 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.